Article
A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.
Cancer medicine - 1 Mar 2026
Xicheng Wang, Yanhong Deng, Yanqiao Zhang, Tianshu Liu, Xianglin Yuan, Jianwei Yang, Tao Zhang, Aimin Zang, Yu Liu, Li Huang, Feng Ye, Hong Zong, Yi Ba, Isabelle Klauck, Jean-Claude Vedovato, Mélanie Groc, Angela Guo, Jian Li, Lin Shen
Abstract excerpt
BACKGROUND: Colorectal cancer (CRC) is a major health burden globally and in China, where 3%-5% of cases involve the BRAFV600E mutation, which is associated with aggressive disease and therefore a poor prognosis. Although the combination of encorafenib and cetuximab has demonstrated improved survival in BRAFV600E mutant metastatic CRC (mCRC), such treatments remain unavailable as chemotherapy-free options in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.